271 related articles for article (PubMed ID: 31110129)
1. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
Distelhorst CW; Bootman MD
Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
[TBL] [Abstract][Full Text] [Related]
2. Targeting Bcl-2-IP
Distelhorst CW
Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
[TBL] [Abstract][Full Text] [Related]
3. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
4. Constitutive IP
Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
[TBL] [Abstract][Full Text] [Related]
5. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
[TBL] [Abstract][Full Text] [Related]
7. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
[TBL] [Abstract][Full Text] [Related]
8. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
9. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
Vervliet T; Lemmens I; Welkenhuyzen K; Tavernier J; Parys JB; Bultynck G
Biochem Biophys Res Commun; 2015 Jul; 463(3):174-9. PubMed ID: 25957473
[TBL] [Abstract][Full Text] [Related]
11. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
12. New Insights in the IP
Parys JB; Vervliet T
Adv Exp Med Biol; 2020; 1131():243-270. PubMed ID: 31646513
[TBL] [Abstract][Full Text] [Related]
13. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
Rong YP; Barr P; Yee VC; Distelhorst CW
Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca(2+) signaling and disease.
Distelhorst CW; Bootman MD
Cell Calcium; 2011 Sep; 50(3):234-41. PubMed ID: 21628070
[TBL] [Abstract][Full Text] [Related]
15. The IP3 receptor as a hub for Bcl-2 family proteins in cell death control and beyond.
Parys JB
Sci Signal; 2014 Feb; 7(312):pe4. PubMed ID: 24518292
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 and IP
Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G
Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
[TBL] [Abstract][Full Text] [Related]
18. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
[TBL] [Abstract][Full Text] [Related]
19. Tracing the evolutionary history of Ca
Rosa N; Shabardina V; Ivanova H; Sebé-Pedrós A; Yule DI; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119121. PubMed ID: 34400171
[TBL] [Abstract][Full Text] [Related]
20. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
